Oruka Therapeutics (DB:HQ1) - Stock Price, News & Analysis

HQ1 Stock Overview

A biotechnology company, develops novel biologics for the treatment of chronic skin diseases.

HQ1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Oruka Therapeutics, Inc. Competitors

Formycon

XTRA:FYB

€879.3m

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€115.1m

2invest

XTRA:2INV

€61.5m

Price History & Performance

Summary of all time highs, changes and price drops for Oruka Therapeutics
Historical stock prices
Current Share Price	US$25.92
52 Week High	US$25.92
52 Week Low	US$22.20
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	16.76%

Recent updates

Shareholder Returns

	HQ1	DE Biotechs	DE Market
7D	0%	0.4%	-0.7%
1Y	n/a	-16.5%	4.0%

Return vs Industry: Insufficient data to determine how HQ1 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how HQ1 performed against the German Market.

Price Volatility

Is HQ1's price volatile compared to industry and market?
HQ1 volatility
HQ1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: HQ1 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HQ1's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Lawrence Klein	orukatx.com

Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases. The company is based in Waltham, Massachusetts.

Oruka Therapeutics, Inc. Fundamentals Summary

How do Oruka Therapeutics's earnings and revenue compare to its market cap?
HQ1 fundamental statistics
Market cap	€790.15m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is HQ1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HQ1 income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did HQ1 perform over the long term?

See historical performance and comparison

Oruka Therapeutics DB:HQ1 Stock Report